AI assistant
Insight Molecular Diagnostics Inc. — Regulatory Filings 2021
Jun 4, 2021
34238_rns_2021-06-04_4a92812e-38ce-4be1-b24d-67baeb518220.zip
Regulatory Filings
Open in viewerOpens in your device viewer
CORRESP 1 filename1.htm
15 Cushing Road Irvine, CA 92618 +844.ONCOCYTE +844.662.6298 +949.409.7600 [email protected] oncocyte.com
June 4, 2021
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
| RE: |
|---|
| Registration |
| Statement on Form S-3 |
| File |
| No. 333-256650 |
Ladies/Gentlemen:
The undersigned registrant, OncoCyte Corporation (the “Company”), hereby requests that its Registration Statement on Form S-3, File No. 333-256650, be declared effective at 9:30 a.m. on Tuesday, June 8, 2021, or as soon thereafter as practicable.
The registrant acknowledges that:
| ● | should
the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission
from taking any action with respect to the filing; |
| --- | --- |
| ● | the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve
the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
| ● | the
Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission
or any person under the federal securities laws of the United States. |
| Sincerely, | |
|---|---|
| OncoCyte | |
| Corporation | |
| By: | /s/ |
| Li Yu | |
| Vice President, Controller |
Field: Page; Sequence: 1; Options: Last
Field: /Page